Wang Ji-Jun, Jing Hong-Mei, Shen Hong-Wei, Xu Jiao-Sheng, Li Min, Gao Zi-Feng, Ke Xiao-Yan
Department of Hematology, Peking University Third Hospital, Beijing 100191, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Dec;18(6):1494-8.
In order to investigate the clinical manifestations, diagnosis, therapy and prognosis of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM), 16 patients with LPL/WM were analyzed retrospectively. The results showed that the average age of 16 patients with LPL/WM was 65.1 years old, the most common syndromes were anemia and hyperviscosity syndrome, bone marrows were composed of small lymphocyte, admixed with variable numbers of plasma cells and plasmacytoid lymphocytes. And lymph node biopsy revealed that most cells expressed B-cell-associated antigen. Among the 16 cases, complete remission was 25%, overall response rate (ORR) was 81.3%, overall survival time was 6 to 108 months. 3 patients died and survival rate was 81.3 %. It is concluded that the clinical course of LPL/WM is typically indolent. These patients can acquire remission in clinic, but can not be cured, some of them can transform into patients with more malignant lymphoma.
为了探讨淋巴浆细胞淋巴瘤/华氏巨球蛋白血症(LPL/WM)的临床表现、诊断、治疗及预后,对16例LPL/WM患者进行回顾性分析。结果显示,16例LPL/WM患者的平均年龄为65.1岁,最常见的症状为贫血和高黏滞综合征,骨髓由小淋巴细胞组成,混有数量不等的浆细胞和浆细胞样淋巴细胞。淋巴结活检显示大多数细胞表达B细胞相关抗原。16例中,完全缓解率为25%,总缓解率(ORR)为81.3%,总生存时间为6至108个月。3例死亡,生存率为81.3%。结论是,LPL/WM的临床病程通常较为惰性。这些患者在临床上可获得缓解,但无法治愈,部分患者可转化为更具侵袭性的淋巴瘤患者。